Dr Thomas Winder, Dr Andrea Sartore-Bianchi and Dr Yu Sunakawa discuss the Clinical Question: Biomarkers: when to test, what to test and what are the consequences?
Dr Thomas Winder, Dr Andrea Sartore-Bianchi and Dr Yu Sunakawa discuss the Clinical Question: Biomarkers: when to test, what to test and what are the consequences?
Dr Thomas Winder is board certified for haematology and medical oncology. Since January 2020 he has been Head of the Department for Haematology and Oncology at the University Teaching Hospital Feldkirch, Austria. In addition, since 2017 he has been President of the Swiss Tumor Molecular Institute in Zürich Switzerland. Dr Winder’s research focuses on molecular markers to individualize medical treatment of cancer patients. He achieved his expertise in internationally renowned laboratories at University of Southern California, Norris Comprehensive Cancer Center, Los Angeles and University Hospital Zürich, Switzerland. His research activity has been honoured by several national and international awards and high impact publications.
Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer
Maximising outcomes for patients with advanced RCC
Medical experts make recommendations for best practice
The latest non-small cell lung cancer data presented at ASCO
GI oncologists review the latest data presented at ASCO 2024
Medical experts discuss the latest learnings from clinical practice